Jennifer B. Marks

Is It Time for a Combination Antihyperglycemic-Statin Pill?

Cardiovascular disease (CVD) associated with type 2 diabetes is undoubtedly multifactorial, with significant risk attributable to oft-associated conditions hypertension and dyslipidemia and, to an as yet undefined extent, hyperglycemia. However, recently published results from the data analysis of the diabetic subgroup of the Heart Protection Study (HPS),1 summarized by Ronald B. Goldberg, MD, in the “Landmark Studies” department of this issue (p. 151), clearly highlight the tremendous risk for CVD conferred by diabetes regardless of other risk factors. The nearly 6,000 diabetic individuals in this study are in a category of patients who may or may …